Hepatology

Chitosan, a dietary fibre derived from chitin in fungi, mushrooms, and crustaceans, has shown potential for weight and fat reduction.

Methods like preoperative time-outs improve communication but can lead to information overload.

Recent developments in machine learning have allowed researchers to reconstruct long-term disease patterns.

A large-scale study finds that the hepatitis E vaccine HEV 239 significantly reduces the risk of symptomatic hepatitis E among individuals with chronic hepatitis B.

The connection between Type 2 diabetes and NAFLD is primarily driven by insulin resistance, which increases free fatty acid levels.

Time-restricted feeding (TRF), limits food intake to a set daily window, such as the 16:8 model.

Mitochondrial impairment is a key factor in MASLD and MASH development, affecting oxidative capacity and energy homeostasis.

Overall, the global hepatitis A landscape has evolved due to shifting transmission routes and pandemic responses.

A clinical trial found that pomegranate peel extract improves liver enzymes, triglycerides, and inflammation markers in NAFLD patients.

These findings challenge existing practices in some institutions that administer prophylactic anticoagulation after liver transplantation.

The study suggests that rencofilstat 225mg/d improves both liver function and portal-systemic shunting in patients with MASH.

Flaxseed powder improves liver fat, metabolism, and gut health in NAFLD patients, offering a natural dietary solution.

Increased copper activity contributes to ageing-related oxidative stress, but targeted chelation therapy may offer a promising intervention.

To improve screening efficiency, it is crucial to identify patients with elevated hepatocellular carcinoma risk while sparing low-risk individuals from unnecessary procedures.

A randomised controlled trial showed that adding reduced glutathione to entecavir therapy can significantly improve liver function, reduce fibrosis, and enhance HBV-DNA clearance in chronic hepatitis B patients.

Immunotherapy, targeted radiation, and a refined surgical technique allowed tumour removal in a liver cancer patient previously ineligible for surgery.

Findings suggest that combining simvastatin and rifaximin does not offer a clinically meaningful advantage in preventing severe complications in patients with decompensated cirrhosis.

Even low levels of air pollution can cause liver inflammation, fibrosis, and metabolic changes linked to fatty liver disease.

cCR predicts survival outcomes in unresectable hepatocellular carcinoma, providing a valuable marker for treatment response and prognosis.

This study revealed an association between elevated hepatic histamine levels, mast cell infiltration, and erythropoietic protoporphyria progression.

Non-selective β-blockers have demonstrated significant potential in preventing decompensation.

By integrating advanced imaging, digital pathology, and molecular analysis, research can refine fibrosis staging and treatment approaches.

A new model predicts HCC risk in noncirrhotic CHB patients, focusing on HBV DNA levels and other key factors.

A clinical trial was conducted to evaluate the efficacy and safety of autologous HBV vaccine-pulsed dendritic cells and their induced T cells.

Data from 22 studies, encompassing 756,088 subjects, including 62,072 Hispanic adults, revealed striking findings.

Alcohol consumption exacerbates the risk of cirrhosis and hepatocellular carcinoma, promoting hepatitis B virus replication and weakening immunity.

Inflammatory and oxidative processes underpin the connection between high Haemoglobin Glycation Index and disease progression.

Lifestyle interventions, particularly achieving a weight loss of over 10%, have been shown to resolve MASH.

A 96-week study finds bulevirtide safe and effective for HDV-related cirrhosis, improving liver health and reducing complications.

Low donor fasting glucose predicts poorer outcomes after LDLT, highlighting its potential as a prognostic marker.

A Mediterranean diet, rich in whole grains, vegetables, fruits, nuts, and olive oil, is proven to improve liver health by reducing inflammation and fat accumulation.

The tool’s performance was consistent across multiple validation cohorts, though accuracy varied slightly, especially when dealing with different patient populations.

The study’s findings demonstrate that hypovolaemic phlebotomy effectively reduces the need for red blood cell transfusions.

Obesity and diabetes mellitus are widely acknowledged risk factors for the development of steatotic liver diseases, contributing to liver cirrhosis and HCC.

Cirrhosis-associated immune dysfunction heightens infection susceptibility through low-grade systemic inflammation and gut-liver axis alterations.

This study demonstrates that combining vibration-controlled transient elastography with retina scanning offers a practical strategy for identifying individuals with potential liver fibrosis.

These findings suggest that dihydroxyacetone phosphate, along with alanine transaminase, could serve as a valuable non-invasive biomarker for liver fibrosis.

These disruptions may play a pathophysiological role in metabolic dysfunction-associated steatotic liver disease development.

Recent research highlights the discovery of 17 novel loci associated with liver triglycerides and 9 linked to liver inflammation.

Recent studies have highlighted the potential of sodium-glucose cotransporter 2 inhibitors, especially ertugliflozin, in improving outcomes for patients with NAFLD and T2DM.

Frailty has emerged as a therapeutic target in advanced chronic liver disease management, with non-pharmacological interventions showing promise.

Lifestyle modifications, particularly dietary changes, have shown potential in reversing MASLD and steatohepatitis.

A recent clinical trial investigated combining time-restricted feeding and flaxseed for MASLD treatment.

Among serum biomarkers, the FIB-4 and APRI scores are widely recognised for assessing advanced fibrosis and cirrhosis.

This study examined the efficacy and safety of pemafibrate in 360 patients with MASLD and hypertriglyceridaemia.

The study involved 419 patients, aged 18–75, with noncirrhotic PSC, who were randomly assigned to receive either cilofexor or a placebo over 96 weeks.

A new study reveals that AI can identify early-stage metabolic-associated steatotic liver disease using electronic health records.

This study assessed neutrophil extracellular traps and DNase activity in patients with chronic hepatitis B-related decompensated cirrhosis to determine their relationship with PVT.

In Spain, HCV prevalence among people experiencing homelessness has declined significantly, from 7.2% in 2019 to 3.4% in 2023.

A new study examined the influence of clinical and histologic risk factors on long-term MASLD outcomes in patients confirmed via liver biopsy.

Rates of liver-related mortality (LRM) in the USA surged by 19.1% from 2018 to 2021, with substantial state-by-state differences…

A newly developed prognostic model predicts liver cancer risk in patients with hepatitis B without cirrhosis, identifying a nonlinear relationship between viral load and cancer risk

Researchers have revealed that a previous paternal hepatitis B virus infection before conception is associated with an increased risk of congenital heart diseases in offspring.

The Baveno VI criteria, combining liver stiffness and platelet count, offer a noninvasive, cost-effective approach to identifying high-risk varices in patients with cirrhosis

The latest clinical guidelines for diagnosing and managing metabolic dysfunction-associated steatotic liver disease, previously known as NAFLD

A novel automated speech analysis platform has been developed to test for minimal hepatic encephalopathy (HE) and to predict overt HE in patients with cirrhosis. 

Researchers have discovered that the use of glucagon-like peptide 1 receptor agonists in patients with MASLD is linked to a significant reduction in the risk of developing cirrhosis and its complications. 

Declines in serum hepatitis B virus RNA during the first and second year of treatment with nucleoside analogues could be indicators of reduced risk for hepatocellular carcinoma.

A recent study has highlighted a concerning gender disparity in access to liver transplants showing that women on the liver transplant waiting list are less likely to undergo a transplant

A lot has changed within the Progressive Familial Intrahepatic Cholestasis (PFIC) landscape in the last few years. The introduction of…

A new study found that vitamin E supplementation can significantly improve liver health in adults with metabolic dysfunction-associated steatotic liver disease.

A recent study demonstrated an AI model that can accurately predict tacrolimus concentrations and suggest optimal dosing for liver transplant recipients.

Recent studies suggest liver stiffness as the primary indicator for assessing long-term risk after Hepatitis C virus treatment

A new model combining clinical and imaging data effectively predicts the absence of high-risk varices in patients with unresectable hepatocellular carcinoma

A recent study has found that up to 13% of patients with dementia may have undiagnosed cirrhosis, potentially contributing to their cognitive decline.

Liver transplantation significantly improves progression-free and overall survival in patients with unresectable colorectal liver metastasis compared to alternative therapies.

Substituting just one meat-based meal with a vegetarian or vegan alternative has been proven to reduce serum ammonia levels for up to 3 hours in patients with cirrhosis, according to a recent study

Prevalence of hepatocellular carcinoma is rising, particularly in Western countries, research shows that a new treatment modality has the potential to transform care for patients

Transgender adults have been found to suffer from cirrhosis twice as often as cisgender individuals, in a recent study.

New research has revealed a link between diabetes and liver cancer, particularly in patients aged 40-54.

Patients with severe acute-on-chronic liver failure faced higher mortality rates than those without while waiting to receive a liver transplant, according to a recent study

Ablation has been shown to be the most cost-effective treatment for hepatocellular carcinoma in a recently published study.